Phase 4 N=285 Dexmedetomidine and Delirium in Patients After Cardiac Surgery
Delirium · C.Surgical Procedure; Cardiac · Postoperative Complications
Primary: Incidence of Postoperative Delirium — 7; 11 Participants — p=0.341
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=96 Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients
Type 2 Diabetes Mellitus
Primary: Change From Baseline to Day 28 in Absolute Plasma Glucose Area Under the Curve (AUC) 0-3hr — -18.005; -45.029; -64.010; -141.848 mg*hrs/dL — p=0.0435
N/A N=100 An Observational Study on Real-world Use and Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to SIADH
Hyponatremia · Syndrome of Inappropriate ADH (SIADH) Secretion
Primary: Change in Sodium Levels From Start of Treatment With Tolvaptan Until Hospital Discharge — 10.3 mmol/L
N/A N=278 Retrospective Review of Mechanically Ventilated Patients Using a Continuous Data Collection System.
Mechanical Ventilation · Acute Respiratory Distress Syndrome · Hypoxic Respiratory Failure
Primary: Successful Extubation — 58; 222 Participants
Phase 4 N=18 Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis
Hypersensitivity
Primary: Symptoms — 15.3; 11.3; 13.3; 9.8 Units on a scale
N/A N=68 Institutional Audit of the Use of Intravenous Acetaminophen in Infants Undergoing Pyloromyotomy
Pyloric Stenosis
Primary: Acetaminophen Dosage — 8.6; 30.7 mg/kg
N/A N=186,394 5 Alpha Reductase Inhibitors And The Risk Of Suicide And Depression
BPH · Depression · Suicide
Primary: Suicide (Based on Administrative Data Elements From Ontario Registrar General Death Database, National Ambulatory Care Reporting System, Hospital Discharge Abstracts…
Phase 2 N=16 Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size
Primary Inoperable Thymoma · Local Recurrent Thymoma
Primary: Percent Change in Tumor Volume From Baseline to EOS — -37.38 percentage of tumor volume
N/A N=71 Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
Epilepsy
Primary: Comparison of Concentrations of Free Thyroid Hormones (FT4 and FT3) as Measured by ED and Automated Kit Assay Method in ESL-exposed Subjects — 12.29; 11.74; 4.20; 3.65…
Phase 2 N=504 MDD POC Study GSK372475 Subjects Depressive Disease
Depressive Disorder
Primary: Mean Change From Randomization at the End of the Treatment Phase in the MADRS Total Score — -16.9; -19.0; -20.5 Score on scale — p=0.485
Phase 4 N=399 Colchicine Or Naproxen Treatment for ACute gouT
Gout
Primary: Change in Pain Intensity — 3.5; 3.8 units on a scale
N/A N=697 Enhancing Self Regulation as a Strategy for Obesity Prevention in Head Start Preschoolers
Obesity
Primary: Change in Body Mass Index Z-score — -0.01; 0.00; -0.04 Z-Score
Phase 4 N=936 Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine
Rhinitis, Allergic, Seasonal
Primary: Mean Change From Baseline Over the Two-week Treatment Period in Nighttime Symptoms Score (NSS) — -1.9; -2.9; -2.0; -0.6 Scores on a scale — p=<0.001
Phase 3 N=640 Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control
Type 2 Diabetes Mellitus
Primary: Change From Baseline in HbA1c From Baseline to Week 24 Provided That it is Prior to Rescue — -3.007; -2.123; -2.794 % HbA1c — p=<0.001
Phase 4 N=42 A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents
Pediatric Obesity · Childhood Obesity
Primary: Apparent Clearance (CL/F) of Phentermine and Topiramate — 7.33; 7.04; 7.33; 7.18 L/h